

BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF
ANTIHYPERTENSIVE DRUGS IN RABBIT PLASMA USING RP-UPLC: A
COMPREHENSIVE REVIEWV. S. Mani Kumar Pinaka^{*1}, Rajiv Kukkar²¹Research Scholar, School of Pharmacy, Raffles University, Neemrana- 301705.²Research Supervisor, Professor, School of Pharmacy, Raffles University, Neemrana- 301705.***Corresponding Author: V. S. Mani Kumar Pinaka**

Research Scholar, School of Pharmacy, Raffles University, Neemrana- 301705.

DOI: <https://doi.org/10.5281/zenodo.23275795>**How to cite this Article:** V. S. Mani Kumar Pinaka^{*1}, Rajiv Kukkar² (2026). Bioanalytical Method Development And Validation Of Antihypertensive Drugs In Rabbit Plasma Using Rp-Uplc: A Comprehensive Review. European Journal of Pharmaceutical and Medical Research, 13(10), 501–507.

This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 16/09/2026

Article Revised on 06/10/2026

Article Published on 10/10/2026

ABSTRACT

Bioanalytical method development is an essential component of pharmaceutical research for the reliable quantification of therapeutic agents in biological matrices. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) provides rapid separation, high chromatographic efficiency, reduced solvent consumption, and improved analytical throughput compared with conventional chromatographic approaches. This review discusses the development and validation of RP-UPLC methods for the determination of antihypertensive drugs in rabbit plasma. Particular emphasis is placed on biological sample preparation, protein precipitation, liquid–liquid extraction, solid-phase extraction, chromatographic optimization, internal-standard selection, detector selection, and validation according to ICH M10 requirements. Critical validation parameters including selectivity, specificity, calibration model, sensitivity, accuracy, precision, recovery, matrix effect, carryover, dilution integrity, and stability are discussed. Bioanalytical methods must demonstrate fitness for their intended purpose and generate reliable concentration data suitable for pharmacokinetic, toxicokinetic, bioavailability, bioequivalence, and other preclinical investigations (ICH, 2022). Recent literature indicates increasing use of chromatographic and hyphenated techniques for quantitative bioanalysis of antihypertensive agents, with particular attention to matrix effects, extraction efficiency, sensitivity, and regulatory compliance (Javid et al., 2025). RP-UPLC therefore represents a valuable analytical platform for rapid and reproducible bioanalysis of antihypertensive drugs in rabbit plasma.

KEYWORDS: RP-UPLC, Bioanalytical Method Development, Method Validation, Antihypertensive Drugs, Rabbit Plasma, Pharmacokinetics, Matrix Effect, Recovery, ICH M10.**1. INTRODUCTION**

Hypertension is a major chronic cardiovascular disorder associated with an increased risk of cardiovascular, cerebrovascular, and renal complications. Pharmacological management commonly involves several therapeutic classes with different mechanisms of action. Reliable measurement of drug concentrations in biological matrices is essential for understanding pharmacokinetic behavior, systemic exposure, absorption, distribution, metabolism, and elimination (Javid et al., 2025).

Bioanalytical methods provide quantitative information regarding therapeutic agents and their metabolites in

biological matrices such as plasma, serum, blood, urine, and tissue samples. These methods support preclinical development, pharmacokinetic studies, toxicokinetic investigations, bioavailability assessment, bioequivalence studies, and therapeutic drug monitoring (ICH, 2022).

The complexity of biological matrices creates significant analytical challenges because endogenous substances may interfere with analyte extraction, chromatographic separation, and detection. Consequently, bioanalytical methods require appropriate sample preparation, chromatographic optimization, and systematic validation before application to study samples (Javid et al., 2025).

RP-UPLC has gained importance in pharmaceutical bioanalysis because of its high-pressure operation, small particle-size stationary phases, improved resolution, shorter analysis time, and reduced mobile-phase consumption. These characteristics can provide efficient separation and high sample throughput while maintaining acceptable analytical performance.

The ICH M10 guideline establishes internationally harmonized recommendations for validation of bioanalytical methods used for quantitative determination of drugs and metabolites in biological matrices. The guideline emphasizes demonstrating that a method is suitable for its intended purpose and generating reliable and reproducible bioanalytical data (ICH, 2022).

2. Importance of Bioanalytical Methods in Antihypertensive Drug Research

Bioanalytical quantification is an important part of pharmaceutical and biomedical research. Accurate measurement of drug concentrations permits evaluation of pharmacokinetic parameters such as maximum concentration, time to maximum concentration, area under the concentration–time curve, elimination half-life, clearance, and volume of distribution.

In preclinical investigations, rabbit plasma may be used to evaluate systemic exposure and pharmacokinetic behavior before further development. Reliable analytical methods are therefore required to distinguish the analyte from endogenous plasma components and accurately quantify concentrations over the expected therapeutic or experimental range.

Bioanalytical methods also contribute to the evaluation of bioavailability and bioequivalence and can support formulation-development studies. The reliability of these applications depends on validated analytical procedures with acceptable accuracy, precision, selectivity, sensitivity, recovery, and stability (ICH, 2022).

Recent reviews have highlighted the increasing importance of chromatographic and mass-spectrometric approaches in antihypertensive drug bioanalysis, particularly because of the need for sensitive detection, efficient extraction, and control of matrix-related interference (Javid *et al.*, 2025).

3. Rabbit Plasma as a Biological Matrix

Rabbit plasma is frequently used in preclinical pharmaceutical research because animal models provide useful information concerning pharmacokinetics and systemic drug exposure. Plasma contains proteins, phospholipids, salts, endogenous metabolites, and other components that may interfere with chromatographic analysis.

The presence of endogenous constituents can affect analyte recovery and detector response. Matrix effects

may therefore produce either enhancement or suppression of the analytical signal, particularly when highly sensitive detection systems are used. Appropriate sample preparation and validation are essential to demonstrate that the biological matrix does not compromise analytical reliability (Javid *et al.*, 2025).

Plasma collection should be performed using an appropriate anticoagulant and under controlled conditions. Samples should be processed promptly and stored under validated conditions to minimize degradation. ICH M10 recommends that stability studies reflect the actual sample collection, processing, storage, and analytical conditions used during the study (ICH, 2022).

4. Sample Preparation Techniques

Sample preparation is one of the most important stages of bioanalytical method development. The primary objectives are to remove endogenous interferences, improve analyte recovery, protect the analytical column, and obtain reproducible extracts.

4.1 Protein Precipitation

Protein precipitation is a simple and rapid sample-preparation technique. Organic solvents are added to plasma to precipitate proteins, followed by vortex mixing and centrifugation. The resulting supernatant can subsequently be injected into the chromatographic system.

The major advantages of protein precipitation include simplicity, low cost, short processing time, and suitability for high-throughput analysis. However, incomplete removal of endogenous components may result in matrix effects or column contamination (Javid *et al.*, 2025).

4.2 Liquid–Liquid Extraction

Liquid–liquid extraction involves transferring the analyte from plasma into an immiscible organic solvent. Extraction efficiency can be influenced by pH, analyte ionization, partition coefficient, solvent selection, and extraction time.

LLE can provide cleaner extracts than simple protein precipitation but generally involves additional handling steps and greater solvent consumption. Optimization of pH and extraction solvent is essential for achieving consistent recovery.

4.3 Solid-Phase Extraction

Solid-phase extraction provides selective purification of analytes using an appropriate sorbent. The general procedure involves conditioning, sample loading, washing, and elution.

SPE can produce clean extracts and reduce matrix interference. However, it requires greater method-development effort and may involve higher consumable

costs than protein precipitation. The choice between precipitation, LLE, and SPE should therefore depend on the analytical objective, matrix complexity, required sensitivity, and intended throughput.

5. RP-UPLC Method Development

RP-UPLC method development involves systematic optimization of chromatographic parameters to obtain adequate retention, resolution, peak shape, sensitivity, and analysis time.

5.1 Selection of Stationary Phase

C18 reversed-phase columns are commonly considered for bioanalytical separations because they provide broad applicability to compounds with moderate to high hydrophobicity. Column dimensions, particle size, pore characteristics, and surface chemistry can influence retention and chromatographic efficiency.

The use of sub-2- μm particles can provide improved efficiency and shorter analysis times. However, increased back pressure requires instrumentation capable of operating at elevated pressures.

5.2 Mobile-Phase Optimization

Mobile-phase composition strongly influences retention time, selectivity, peak shape, and sensitivity. Organic modifiers such as acetonitrile or methanol may be combined with aqueous buffers.

Optimization should consider buffer concentration, pH, organic-phase proportion, gradient or isocratic conditions, and compatibility with the selected detector. Proper optimization can reduce analysis time while maintaining sufficient separation from endogenous plasma components.

5.3 Flow Rate and Column Temperature

Flow rate affects retention, peak width, pressure, and total analysis time. Column temperature can influence viscosity, analyte retention, selectivity, and peak shape. These parameters should be optimized systematically rather than selected independently.

5.4 Detection

UV or PDA detection can be suitable for compounds possessing adequate chromophores and sufficient concentration in biological samples. More selective detectors, particularly mass spectrometric systems, can provide enhanced sensitivity and selectivity for low-concentration analytes.

Recent literature indicates that LC-MS-based approaches are increasingly used in antihypertensive bioanalysis because of their sensitivity and ability to analyze complex biological matrices (Javid *et al.*, 2025).

6. Selection of Internal Standard

An internal standard is incorporated into bioanalytical procedures to compensate for variability associated with

sample preparation, injection, and instrumental response. The internal standard should exhibit analytical behavior similar to the target analyte while remaining adequately separated from the analyte and endogenous components.

The selection should consider extraction behavior, chromatographic retention, detector response, stability, and absence from the biological matrix. Stable-isotope-labelled compounds are often preferred in mass-spectrometric methods when available because of their similar physicochemical and extraction characteristics.

7. Bioanalytical Method Validation According to ICH M10

ICH M10 provides harmonized recommendations for bioanalytical method validation and study sample analysis. The primary objective is to demonstrate that a method is suitable for its intended purpose (ICH, 2022).

7.1 Selectivity

Selectivity demonstrates the ability of the analytical method to differentiate the analyte from endogenous matrix components, metabolites, degradation products, and other potentially interfering substances.

Blank biological samples from multiple sources should be examined to establish the absence of significant interference at the retention time of the analyte and internal standard (ICH, 2022).

7.2 Calibration Curve and Linearity

The calibration curve establishes the relationship between analytical response and analyte concentration. Appropriate calibration standards should cover the expected concentration range of study samples.

The calibration model should be selected based on the concentration–response relationship and supported by appropriate statistical and experimental evaluation. The calibration range should adequately cover the lower and upper concentrations expected during sample analysis (ICH, 2022).

7.3 Lower Limit of Quantification

The lower limit of quantification (LLOQ) represents the lowest concentration that can be quantitatively measured with acceptable accuracy and precision.

A suitable LLOQ is particularly important in pharmacokinetic studies because plasma concentrations may decline substantially during the elimination phase.

7.4 Accuracy

Accuracy represents the closeness of the measured concentration to the nominal concentration. It is generally evaluated using quality-control samples at multiple concentration levels.

ICH M10 specifies acceptance criteria for accuracy and precision according to the intended bioanalytical application (ICH, 2022).

7.5 Precision

Precision represents the degree of agreement between repeated measurements. It is generally evaluated as within-run and between-run precision.

Precision is commonly expressed as percentage coefficient of variation (%CV). Appropriate precision demonstrates that the method can generate reproducible concentration measurements.

7.6 Recovery

Recovery evaluates the efficiency of analyte extraction from the biological matrix. It is determined by comparing extracted samples with appropriate reference preparations.

High recovery is desirable but does not necessarily need to approach 100%, provided that recovery is consistent and reproducible across concentration levels.

7.7 Matrix Effect

Matrix effect is an important consideration in biological analysis. Endogenous plasma components can influence detector response and may result in signal suppression or enhancement.

Matrix effects should be evaluated using appropriate matrix samples and multiple sources where applicable. Their assessment is particularly important for highly sensitive detection systems (ICH, 2022; Javid *et al.*, 2025).

7.8 Carryover

Carryover occurs when analyte from a previous injection affects the subsequent sample. It can result in falsely elevated concentrations, particularly near the LLOQ.

Carryover should therefore be evaluated during method validation, and appropriate washing procedures should be incorporated into the chromatographic sequence where necessary.

7.9 Stability

Stability studies demonstrate that the analyte remains stable throughout sample collection, processing, storage, and analysis.

Important stability assessments may include.

Stability Studies in Bioanalytical Method Validation

1. Bench-top Stability

Bench-top stability evaluates the stability of the analyte in the biological matrix during sample handling at laboratory temperature before extraction. In a typical bioanalytical study, aliquots of rabbit plasma containing low- and high-quality-control concentrations are maintained at room temperature for a period representing

the maximum expected sample-processing time. For example, plasma samples may be maintained at **25 ± 2°C for 4–6 hours** before extraction. Following the specified period, the samples are processed and analyzed against freshly prepared comparison samples. If a quality-control sample prepared at **20 ng/mL** produces a measured concentration of **19.2 ng/mL**, corresponding to 96.0% of the nominal concentration, the result may demonstrate acceptable stability when it satisfies the predefined validation criteria. Bench-top stability is important because delays during thawing, aliquoting, centrifugation, and sample preparation may potentially cause analyte degradation (ICH, 2022; Bansal & DeStefano, 2007).

2. Freeze–Thaw Stability

Freeze–thaw stability evaluates the ability of the analyte to remain stable during repeated freezing and thawing of biological samples. Quality-control plasma samples are subjected to the number of freeze–thaw cycles expected during the study. For example, samples may be frozen at **–20°C or –80°C**, completely thawed under controlled conditions, and subsequently refrozen. This process may be repeated for three cycles when three cycles represent the anticipated sample-handling conditions. After completion of the required cycles, the samples are processed and analyzed against appropriate comparison samples. For example, a plasma sample with a nominal concentration of **100 ng/mL** may produce a measured concentration of **97–103 ng/mL** after the evaluated freeze–thaw cycles. If the resulting accuracy and precision satisfy the predefined criteria, the analyte can be considered stable under the tested conditions. Freeze–thaw stability is important because biological samples may be repeatedly removed from and returned to frozen storage during sample processing and analysis (ICH, 2022; Viswanathan *et al.*, 2007).

3. Long-Term Stability

Long-term stability determines whether the analyte remains stable in the biological matrix throughout the maximum anticipated storage period. Quality-control samples are stored under the same conditions intended for study samples, such as **–20°C or –80°C**, for a predefined duration. For example, if rabbit plasma samples are expected to remain frozen for approximately **30 days**, appropriately prepared stability samples can be stored for the corresponding period and subsequently analyzed against freshly prepared quality-control samples. If a sample with a nominal concentration of **50 ng/mL** produces a measured concentration of **49.1 ng/mL**, corresponding to 98.2% of the nominal value, the result may indicate adequate stability when it meets the applicable acceptance criteria. Long-term stability is particularly important in pharmacokinetic and toxicokinetic investigations because biological samples may be stored for extended periods before analysis (ICH, 2022; Shah *et al.*, 2000).

4. Processed-Sample Stability

Processed-sample stability evaluates the stability of the analyte after completion of sample preparation and before or during chromatographic analysis. This assessment is important when a large number of biological samples must be analyzed sequentially. For example, extracted rabbit plasma samples may be maintained in an autosampler under validated temperature conditions, such as 5–10°C, for the maximum period expected during the analytical sequence. A quality-control sample with a nominal concentration of 80 ng/mL, for example, may produce a concentration of 78.8 ng/mL after the specified autosampler period, corresponding to 98.5% of the nominal value. If the result satisfies the established accuracy and precision requirements, the processed sample may be considered stable for the evaluated period. This study confirms that the analyte does not undergo significant degradation after extraction and during the time required for chromatographic analysis (ICH, 2022; Bansal & DeStefano, 2007).

5. Stock-Solution Stability

Stock-solution stability evaluates the stability of concentrated analyte and internal-standard solutions used to prepare calibration standards and quality-control samples. Stock solutions are prepared at known concentrations and stored under predefined conditions for a specified period. For example, a stock solution prepared at 1 mg/mL may be stored at 2–8°C for the intended storage period and subsequently compared with a freshly prepared solution. If the stored solution provides an analytical response corresponding to approximately 99.0% of the freshly prepared solution, with acceptable variation, it may be considered stable for the tested period. Evaluation of stock-solution stability is essential because degradation or concentration changes in reference solutions can directly affect the preparation of calibration standards and quality-control samples and consequently influence quantitative results (ICH, 2022; Viswanathan *et al.*, 2007).

6. Working-Solution Stability

Working-solution stability assesses the stability of diluted solutions prepared from stock solutions and routinely used for preparing calibration standards, quality-control samples, or internal-standard solutions. These solutions are stored under their intended laboratory conditions for the maximum period during which they are expected to be used. For example, a working solution prepared at 10 µg/mL may be stored at 2–8°C for 24–48 hours and compared with a freshly prepared solution. If the stored solution provides an analytical response corresponding to approximately 98–102% of the freshly prepared solution and demonstrates acceptable precision, the solution may be considered stable for the tested period. This evaluation is important because degradation, evaporation, adsorption to containers, or other physicochemical changes can alter the concentration of working solutions and subsequently

affect the accuracy of calibration and quality-control samples (ICH, 2022; Bansal & DeStefano, 2007).

Overall Importance of Stability Evaluation

Collectively, stability studies demonstrate that the analyte remains sufficiently stable throughout the complete bioanalytical workflow, from preparation and storage of reference solutions through biological sample handling, extraction, storage, and instrumental analysis. For example, a rabbit plasma sample may be collected, frozen, thawed, maintained at laboratory temperature, extracted, stored in an autosampler, and finally injected into the RP-UPLC system. Each stage represents a potential opportunity for analyte degradation. Evaluation of stability under conditions that reflect actual sample handling therefore provides confidence that the reported concentrations represent the true analyte content rather than changes caused by storage or processing (ICH, 2022). Stability experiments should be appropriately designed to cover the relevant storage conditions, durations, concentrations, and handling procedures used during the bioanalytical study.

7.10 Dilution Integrity

Dilution integrity demonstrates that samples exceeding the upper calibration range can be diluted and accurately quantified without compromising method performance.

The dilution procedure used during sample analysis should be consistent with the conditions evaluated during validation (ICH, 2022).

8. Applications of RP-UPLC Bioanalytical Methods

Validated RP-UPLC methods can support several areas of pharmaceutical research, including.

Pharmacokinetic Studies

Quantitative plasma concentration data can be used to characterize absorption, distribution, metabolism, and elimination and to calculate important pharmacokinetic parameters.

Bioavailability Studies

Bioanalytical methods can support comparisons of systemic exposure following different formulations or administration conditions.

Bioequivalence Studies

Reliable concentration measurements are essential for comparing pharmacokinetic exposure between pharmaceutical products.

Toxicokinetic Studies

Bioanalysis can provide information regarding systemic exposure during nonclinical safety studies.

Therapeutic Drug Monitoring

Where clinically appropriate, validated quantitative methods can assist in monitoring circulating

concentrations and supporting individualized pharmacotherapy.

9. Green and Sustainable Bioanalysis

Sustainable analytical chemistry has become increasingly important in pharmaceutical analysis. Conventional bioanalytical procedures may consume considerable quantities of organic solvents and generate substantial laboratory waste.

RP-UPLC can contribute to greener analytical workflows through shorter run times, lower mobile-phase consumption, reduced sample volumes, and higher sample throughput. Simplified sample preparation, particularly protein precipitation, may further reduce solvent and consumable requirements.

Future bioanalytical methods should therefore consider not only analytical performance but also solvent consumption, energy requirements, waste generation, sample volume, and overall environmental impact.

10. Current Challenges

Despite significant improvements in chromatographic technology, several challenges remain in biological analysis.

The major challenges include.

1. Matrix interference.
2. Variable extraction efficiency.
3. Low analyte concentrations.
4. Instability during storage.
5. Carryover.
6. Column contamination.
7. Selection of an appropriate internal standard.
8. Complex sample preparation.
9. Requirement for rapid analysis.
10. Need for compliance with regulatory expectations.

Recent literature also identifies matrix effects and co-medication-related interference as important areas requiring continued attention in bioanalysis (Javid *et al.*, 2025).

11. Future Perspectives

Future developments in RP-UPLC bioanalysis are expected to emphasize rapid, miniaturized, automated, and environmentally sustainable analytical procedures. Integration with high-resolution detection, automated sample preparation, microextraction techniques, and advanced data-processing approaches may improve analytical efficiency.

Artificial intelligence and machine-learning approaches may also contribute to chromatographic optimization, prediction of retention behavior, identification of analytical conditions, and interpretation of complex bioanalytical datasets. However, such approaches require appropriate validation and scientific justification before regulatory application (Javid *et al.*, 2025).

The continued harmonization of bioanalytical requirements through ICH M10 is expected to improve consistency in method development, validation, documentation, and study sample analysis across regulatory regions (ICH, 2022).

12. Research Gaps

Although numerous bioanalytical methods have been reported, further research is required in the following areas.

- Development of simultaneous multi-analyte methods.
- Reduction of plasma sample volume.
- Improvement of extraction recovery.
- Minimization of matrix effects.
- Development of rapid protein-precipitation procedures.
- Application of automated sample preparation.
- Reduction of organic-solvent consumption.
- Development of environmentally sustainable analytical workflows.
- Application of chemometric and AI-assisted method optimization.
- Improved standardization of bioanalytical procedures for animal plasma matrices.

13. CONCLUSION

RP-UPLC is a valuable analytical platform for the development of rapid, sensitive, precise, and reproducible bioanalytical methods for antihypertensive drugs in rabbit plasma. Successful method development requires systematic optimization of sample preparation, chromatographic conditions, detection, and internal-standard selection. Comprehensive validation according to ICH M10 is essential to establish selectivity, calibration performance, accuracy, precision, recovery, matrix effects, carryover, and stability (ICH, 2022).

Rabbit plasma provides a useful preclinical matrix for pharmacokinetic and toxicokinetic investigations, although its endogenous components can present significant analytical challenges. Proper sample preparation and chromatographic optimization are therefore essential for obtaining reliable results. Current trends toward shorter analysis times, lower solvent consumption, automation, greener sample preparation, and advanced data-processing approaches are likely to further improve bioanalytical workflows.

Overall, RP-UPLC-based bioanalytical methods provide an efficient approach for quantitative pharmaceutical analysis and can support preclinical pharmacokinetic, bioavailability, bioequivalence, and toxicological investigations when appropriately developed and validated.

14. REFERENCES

1. Ardrey, R. E. (2003). *Liquid chromatography–mass spectrometry: An introduction*. John Wiley & Sons.
2. Bansal, S., & DeStefano, A. (2007). Key elements of bioanalytical method validation for small molecules. *The AAPS Journal*, 9(1): E109–E114.
3. Dong, M. W. (2019). *Modern HPLC for practicing scientists* (2nd ed.). Wiley.
4. Ermer, J. (2001). Validation in pharmaceutical analysis. Part I: An integrated approach. *Journal of Pharmaceutical and Biomedical Analysis*, 24(5–6): 755–767.
5. International Council for Harmonisation. (2022). *ICH harmonised guideline M10: Bioanalytical method validation and study sample analysis*. ICH.
6. Javid, S., Ramya, K., Ahmed, M. G., Zahiya, N., Sha, F., & Sultana, R. (2025). Bioanalysis of antihypertensive drugs by LC-MS: A fleeting look at the regulatory guidelines and artificial intelligence. *Bioanalysis*, 17(7): 471–487.
7. Jin, Y., He, Y., Di, X., Fu, L., Qi, X., Liu, R., Zheng, L., Wang, Y., Zhong, H., & Wang, Z. (2022). Simultaneous determination and pharmacokinetics study of antihypertensive agents and their major metabolite in human plasma, urine and peritoneal dialysis fluid by UPLC-MS/MS. *Journal of Chromatography B*, 1208: 123402.
8. Kazakevich, Y., & Lobrutto, R. (2007). *HPLC for pharmaceutical scientists*. Wiley-Interscience.
9. Matuszewski, B. K., Constanzer, M. L., & Chavez-Eng, C. M. (2003). Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. *Analytical Chemistry*, 75(13): 3019–3030.
10. Niessen, W. M. A. (2006). *Liquid chromatography–mass spectrometry* (3rd ed.). CRC Press.
11. Shah, V. P., Midha, K. K., Findlay, J. W. A., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., Tonelli, A., Viswanathan, C. T., & Yacobi, A. (2000). Bioanalytical method validation—A revisit with a decade of progress. *Pharmaceutical Research*, 17: 1551–1557.
12. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2010). *Introduction to modern liquid chromatography* (3rd ed.). John Wiley & Sons.
13. Swartz, M. E. (2005). UPLC™: An introduction and review. *Journal of Liquid Chromatography & Related Technologies*, 28(7–8): 1253–1263.
14. Swartz, M. E. (2008). Ultra performance liquid chromatography (UPLC): An introduction and review. *Journal of Liquid Chromatography & Related Technologies*, 31(10): 1481–1502.
15. U.S. Food and Drug Administration. (2018). *Bioanalytical method validation: Guidance for industry*. Center for Drug Evaluation and Research.
16. U.S. Food and Drug Administration. (2022). *M10 bioanalytical method validation and study sample analysis: Guidance for industry*. Center for Drug Evaluation and Research.
17. Viswanathan, C. T., Bansal, S., Booth, B., DeStefano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., & Weiner, R. (2007). Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. *Pharmaceutical Research*, 24: 1962–1973.
18. Wren, S. A. C., & Tchelitcheff, P. (2006). Use of ultra-performance liquid chromatography in pharmaceutical development. *Journal of Chromatography A*, 1119(1–2): 140–146.
19. Bansal, S., & DeStefano, A. (2007). Key elements of bioanalytical method validation for small molecules. *The AAPS Journal*, 9(1): E109–E114.
20. International Council for Harmonisation. (2022). *ICH harmonised guideline M10: Bioanalytical method validation and study sample analysis*. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
21. Shah, V. P., Midha, K. K., Findlay, J. W. A., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., Tonelli, A., Viswanathan, C. T., & Yacobi, A. (2000). Bioanalytical method validation—A revisit with a decade of progress. *Pharmaceutical Research*, 17: 1551–1557.